Halozyme Therapeutics | HALO - 流动资产



金融业
股票价格
USD
资产
USD 2.67B
现金及等价物
USD 309.75M
销售成本
USD 108.75M
流动资产
USD 1B
流动负债
USD 363.21M
债务
USD 2.14B
EBIT
USD -61.77M
EBITDA
USD 219.57M
员工
350
EPS每股收益
USD 1.6
股本和储备
USD 219.64M
销售毛利
USD 297.47M
债务利息支出
USD 5.51M
贷款资金
USD 1.94B
市值
USD 8.71B
净收入
USD 150.05M
营业费用
USD 192.19M
营业利润
USD -61.77M
普通股股本
USD 118.52M
PE价格收益
11.35
税前利润
USD 180.33M
销售收入
USD 377M
销售和管理费用
USD 46.29M
股票
USD 155.47M
贸易债权人
USD 14.1M
应收帐款人
USD 457.99M


流动资产 更改 日
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Baxter International USD 6.85B 25M 2026-03
Cara Therapeutics USD 31.54M 6.9M 2025-12
Cytokinetics USD 839.46M 77.51M 2026-03
DBV Technologies USD 212.94M 124.06M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
MannKind USD 251.16M 40.42M 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Pfizer USD 42.82B 76M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12